Quidelortho Corp
F:QL1A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quidelortho Corp
Total Liabilities
Quidelortho Corp
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidelortho Corp
F:QL1A
|
Total Liabilities
$3.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
48%
|
CAGR 10-Years
35%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities
$19.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Liabilities
$3.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities
$25.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities
$34.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities
$2.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Quidelortho Corp
Glance View
QuidelOrtho Corporation has emerged as a significant player in the realm of diagnostic healthcare, formed through the strategic merger of Quidel Corporation and Ortho Clinical Diagnostics. This union brought together Quidel's expertise in rapid diagnostic testing solutions and Ortho Clinical's strengths in in vitro diagnostics, aiming to create a powerhouse capable of addressing the evolving needs of modern healthcare systems globally. Quidel, originally known for its swift point-of-care diagnostic tools for infectious and other diseases, found a strategic complement in Ortho Clinical's laboratory-based testing and transfusion medicine capabilities. This merger allowed QuidelOrtho to leverage both companies’ technological innovations and established customer bases, effectively broadening their market reach and ensuring a diversified revenue stream. The company operates by developing, manufacturing, and marketing a comprehensive range of diagnostic solutions that serve both healthcare professionals and patients alike. At the heart of QuidelOrtho's operations is its commitment to enhancing patient outcomes through precision testing—a focus that aligns with the growing demand for accurate and reliable diagnostic information. Revenue generation stems from its extensive portfolio, which includes point-of-care testing kits, laboratory instruments, and other diagnostic equipment. By providing indispensable tools that aid in the early detection and management of diseases, QuidelOrtho not only supports healthcare providers in improving clinical outcomes but also positions itself as a crucial contributor to the global medical landscape. Its varied product lines and strategic innovations continue to reinforce its role in promoting public health and advancing medical diagnostics.
See Also
What is Quidelortho Corp's Total Liabilities?
Total Liabilities
3.8B
USD
Based on the financial report for Dec 28, 2025, Quidelortho Corp's Total Liabilities amounts to 3.8B USD.
What is Quidelortho Corp's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
35%
Over the last year, the Total Liabilities growth was 12%. The average annual Total Liabilities growth rates for Quidelortho Corp have been -1% over the past three years , 48% over the past five years , and 35% over the past ten years .